Pfizer News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

14.09.22	Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022 (Businesswire)
14.09.22	Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine (Businesswire)
12.09.22	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union (RSS)
12.09.22	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union (Businesswire)
09.09.22	FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata (Businesswire)
07.09.22	FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women (Businesswire)
06.09.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
06.09.22	Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action (Businesswire)
01.09.22	Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences (Businesswire)
01.09.22	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union (RSS)
01.09.22	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union (Businesswire)
31.08.22	Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older (Businesswire)
31.08.22	Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older (RSS)
30.08.22	So sieht die Aktionärsstruktur beim Corona-Impfstoffentwickler BioNTech aus (finanzen.ch) Der Corona-Impfstoff aus dem Hause BioNTech hat nicht nur die Börse euphorisch gestimmt, sondern auch den Mitgründer und CEO des Konzerns, Ugur Sahin, in die globale Rangliste der Superreichen katapultiert.» mehr
26.08.22	Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine (RSS)
25.08.22	Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate (Businesswire)
23.08.22	Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age (RSS)
23.08.22	Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age (Businesswire)
22.08.22	Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine (RSS)
22.08.22	Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine (Businesswire)
19.08.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
12.08.22	Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants (Businesswire)
08.08.22	Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15 (Businesswire)
08.08.22	Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology (Businesswire)
28.07.22	PFIZER REPORTS SECOND-QUARTER 2022 RESULTS (Businesswire)
27.07.22	Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design (RSS)
27.07.22	General statement of acquisition of beneficial ownership (RSS)
19.07.22	Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 Adapted Bivalent Vaccine Candidate (RSS)
08.07.22	Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age (RSS)
08.07.22	Pfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children Ages 6 Months to less than 5 Years with COMIRNATY® (RSS)
07.07.22	GlaxoSmithKline-Aktie stärker: GSK-Aktionäre geben grünes Licht für Ausgliederung von Consumer-Health-Geschäft (Dow Jones) Die Aktionäre von GlaxoSmithKline (GSK) haben die geplante Ausgliederung und separate Börsennotierung der Consumer-Healthcare-Sparte Haleon genehmigt.» mehr
30.06.22	Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™ (Businesswire)
29.06.22	Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine (RSS)
29.06.22	Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine (Businesswire)
29.06.22	Statement of acquisition of beneficial ownership by individuals (RSS)
28.06.22	Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus (Businesswire)
28.06.22	Statement of acquisition of beneficial ownership by individuals (RSS)
25.06.22	Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron (RSS)
25.06.22	Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron (Businesswire)
24.06.22	Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts (Businesswire)
23.06.22	Pfizer Declares Third-Quarter 2022 Dividend (Businesswire)
20.06.22	Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15 (Businesswire)
17.06.22	Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age (Businesswire)
17.06.22	Tilray Brands Gets Festive with its 2024 Holiday Beverage Gift Guide (RSS)
15.06.22	Breckenridge Distillery's Latest Creation is the Perfect Addition to Your Holiday Bar: Breckenridge Candy Cane Vodka (RSS)
14.06.22	Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA (Businesswire)
09.06.22	Pfizer Completes Acquisition of ReViral (Businesswire)
09.06.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
08.06.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
06.06.22	Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S. (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swiss Re	133.65	4.58 %	K V
Swiss Life Hldg	693.00	0.84 %	K V
Zurich Insur Gr	552.40	0.84 %	K V
Kuehne+Nagel Int	206.50	0.73 %	K V
Sonova Hldg	294.20	0.65 %	K V
Sika	227.90	-1.17 %	K V
Part Grp Hldg	1’263.50	-1.63 %	K V
Geberit	538.00	-1.65 %	K V
Alcon	75.24	-1.72 %	K V
Lonza Grp	534.80	-2.44 %	K V